Crescent Biopharma CBIO
NASDAQ CBIO
$13.17 +0.10 (+0.77%)
At close: Oct 21, 2026 · 4:00 PM EDT

Crescent Biopharma (CBIO) Preferred Stock Liabilities (2024 - 2025)

Updated

Crescent Biopharma's Preferred Stock Liabilities came in at $4 million for Q1 2025, unchanged from the prior quarter.

Analysis

Crescent Biopharma (CBIO) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn -
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn -
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Crescent Biopharma 401.19 Mn -306.10 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 4.00 Mn
Dec 31, 2024 4.00 Mn
Sep 30, 2024 4.00 Mn
API Access

Crescent Biopharma Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=CBIO&period=max&api_key=YOUR_API_KEY